NCT07057765View on ClinicalTrials.gov

Predictive Value of CRP, Albumin, CAR, and mGPS in Treatment Outcomes of DLBCL

RecruitingOBSERVATIONAL
Enrollment

40

Participants

Timeline

Start Date

May 5, 2025

Primary Completion Date

May 31, 2026

Study Completion Date

August 31, 2026

Conditions
DLBCL - Diffuse Large B Cell LymphomaMarkers of Inflammation
Interventions
DRUG

Observational Assessment of Standard R-CHOP Treatment

Patients will receive R-CHOP chemotherapy (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) as part of routine clinical care. The study does not assign or modify treatment. Data will be collected to assess the association between inflammatory markers and clinical outcomes.

Trial Locations (1)

1181

RECRUITING

Clinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Ain Shams University, Cairo

All Listed Sponsors
lead

Ain Shams University

OTHER